The comparison Losartan and medical combination of Losartan and pyridoxamine on reducing proteinuria in patients with diabetes type II

Abstract: Background and purpose: The diabetic nephropathy is one of final stage causes of renal disease. The angiotensin II locally increases because of hyperglycemia in kidney and causes renal lesions induction especially, glomerular lesions. Thus, in the present research, we try to treat patients suffering from diabetic nephropathy by Losartan, pyridoxamine, and study useful effects of these drugs on disease progression process. Methodology: In the present clinical experimental study, 44 patients with diabetic type II were selected without regard to sex sequentially and categorized in two groups randomly. First group (n = 22) were treated with Losartan by dose 25 mg every 12h for 2 months solely and tests controlled while start of drug and next two months. The second group (n = 22) were under treatment with conjoint Losartan (25mg/12h) and pyridoxamine (25mg) and tests controlled before and after 2 months treatment. Results: In case group, the average measured sodium before and after treatment were 146139.95±4.17 and 138.33±2.28, the mean triglyceride measured before and after treatment were 231.28±106.05 and 179.66±116.06, mean lipid -peroxide measured before and after treatment 3.39±1.57 and 1.79±0.84, the mean 24-h urine protein measured before and after treatment were 3157.38±2330.47 and 1587.52±1695m 91 and finally the mean uric acid measured before and after treatment were 8.46±2.13 and 6.69±2.28 respectively. In control group the mean sodium measured before and after treatment were 138.85±6 and 136.9±4.74, the mean triglyceride measured before and after treatment were 181.5±95.14 and 172.85±56.81, the mean lipid peroxide measured before and after treatment were 2.88±1,34 and 2.02±0.83, the mean uric protein 24h measured before and after treatment were 1087.18±1021.81 and 425.52±447.97 and finally the mean uric acid were 8.03±1.75 and 6.08±1.95 respectively. Conclusion: In the group treated by Losartan, there were meaningful difference between before and after treatment in the cases of cholesterol, blood sugar, uric acid, 24-h urine protein and lipid peroxide. In the group under treatment by combination of Losartan and pyridoxamine, there were meaningful difference between pre and pro treatment in the cases of triglycerides, blood suger, uric acid, 24-h urea protein and lipid peroxide. It is noticeable to say that there was more meaningful difference between pre and pro treatment in the group under treatment by combination of Losartan and pyridoxamine than group treated by Losartan. Thus, with attention to ontained results, it is recommended use of Losartan in combination with pyridoxamine